Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD

Hudson Bay Capital Management LP lowered its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,075,000 shares of the biopharmaceutical company’s stock after selling 137,690 shares during the period. Hudson Bay Capital Management LP owned about 0.67% of Amicus Therapeutics worth $16,351,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its holdings in Amicus Therapeutics by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company’s stock valued at $22,061,000 after buying an additional 194,213 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Amicus Therapeutics by 11.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company’s stock worth $8,751,000 after acquiring an additional 113,803 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Amicus Therapeutics by 37.1% in the 1st quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company’s stock worth $1,395,000 after acquiring an additional 46,218 shares during the period. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the 1st quarter worth approximately $30,000. Finally, Bank of Montreal Can purchased a new position in Amicus Therapeutics in the 2nd quarter valued at approximately $144,000.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 19th. TD Cowen lowered Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price on the stock. in a report on Monday, December 22nd. Citigroup restated a “neutral” rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $14.50 price objective (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $15.39.

Amicus Therapeutics Trading Up 0.1%

Shares of Amicus Therapeutics stock opened at $14.38 on Friday. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $14.39. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. The business has a 50 day moving average price of $14.33 and a 200 day moving average price of $11.33. The company has a market capitalization of $4.52 billion, a P/E ratio of -179.75 and a beta of 0.43.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). The company had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. Amicus Therapeutics’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.09 EPS. Sell-side analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Insider Activity

In related news, CEO Bradley L. Campbell sold 22,500 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total transaction of $322,875.00. Following the sale, the chief executive officer owned 998,680 shares of the company’s stock, valued at $14,331,058. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is owned by corporate insiders.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.